Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF2R | P11717 | 1/20 | 0.31 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.30 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.30 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.30 |
| ▸ | GJB2 | P29033 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19389554 | 0.89 | IGF2R (0.34) | IGF2RGJB2 | |
| SCHEMBL17520392 | 0.89 | IGF2R (0.34) | IGF2RGJB2 | |
| SCHEMBL16248353 | 0.86 | SSTR1 (0.30) | — | |
| SCHEMBL19577793 | 0.86 | SSTR1 (0.30) | — | |
| SCHEMBL24742680 | 0.80 | LGALS8 (0.33) | LGALS8 | |
| SCHEMBL14037462 | 0.79 | LGALS8 (0.32) | IGF2RLGALS8LGALS3LGALS4 | |
| SCHEMBL19143464 | 0.79 | LGALS8 (0.32) | IGF2RLGALS8LGALS3LGALS4 | |
| SCHEMBL19577797 | 0.79 | — | — | |
| SCHEMBL21474778 | 0.79 | — | — | |
| SCHEMBL16248351 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10363266-B2 | Antisense-oligonucleotides as inhibitors of TGF-R signaling | Neurovision Pharma GmbH (DE) | 2019-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10363266-B2 | Antisense-oligonucleotides as inhibitors of TGF-R signaling | TGFBR1, TGFBR2, TGFB1 | IGF2R 169/4885LGALS8 1264/4885LGALS3 2607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.